Shopping Cart
- Remove All
Your shopping cart is currently empty
JZP-361 is a specific MAGL inhibitor with IC50s of 46 nM, 7.24 μM, and 1.79 μM for human recombinant MAGL, human recombinant FAAH, and human hABHD6. JZP-361 displays anti-histaminergic activities. JZP-361 can be used in studies about asthma.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 5 mg | $38 | In Stock | |
| 10 mg | $59 | In Stock | |
| 25 mg | $118 | In Stock | |
| 50 mg | $197 | In Stock | |
| 100 mg | $296 | In Stock | |
| 200 mg | $419 | In Stock |
| Description | JZP-361 is a specific MAGL inhibitor with IC50s of 46 nM, 7.24 μM, and 1.79 μM for human recombinant MAGL, human recombinant FAAH, and human hABHD6. JZP-361 displays anti-histaminergic activities. JZP-361 can be used in studies about asthma. |
| Targets&IC50 | MAGL (human):46 nM, H1 receptor:6.81 (pA2), ABHD6 (human):1.79 μM, FAAH (human):7.24 μM |
| In vitro | JZP-361 shows the affinity of H1 antagonistic with a pA2 of 6.81). JZP-361(≤10 μM) does not show cannabinoid receptor activity. JZP-361 displays favorable interactions within the important hydrogen-bonding of the carbonyl oxygen to the oxyanion hole[1]. |
| Synonyms | JZP361, JZP 361 |
| Molecular Weight | 405.88 |
| Formula | C22H20ClN5O |
| Cas No. | 1680193-80-9 |
| Smiles | Clc1ccc2c(CCc3cccnc3C2=C2CCN(CC2)C(=O)n2cncn2)c1 |
| Relative Density. | 1.41 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | Ethanol: 36.5 mg/mL (89.93 mM), Sonication is recommended. DMSO: 1 mg/mL (2.46 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO/Ethanol
Ethanol
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.